Skip to main content
. 2023 Nov 15;16:2447–2458. doi: 10.2147/RMHP.S436750

Table 2.

Summary of Cost and Outcome Results in the Base-Case Analysis

Strategy Cost QALY Incr Cost Incr QALY ICER
Tislelizumab + chemotherapy $26,450.77 1.35 $9763.62 0.46 21,062.09
Chemotherapy alone $16,687.15 0.89

Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; Incr, incremental.